ESMO clinical practice guidelines for metastatic NSCLC in 2018 and Canadian consensus in 2019 recommended that continuous use of current targeted therapy in combination with local treatment could be considered as an approach in certain selected patients with limited extra‐CNS oligo‐PD in EGFR‐mutation positive NSCLC.98, 99. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.